|
NRG-RTOG 1106/ACRIN 6697: A phase IIR trial of standard versus adaptive (mid-treatment PET-based) chemoradiotherapy for stage III NSCLC—Results and comparison to NRG-RTOG 0617 (non-personalized RT dose escalation). |
| |
|
Honoraria - Varian Medical Systems |
Speakers' Bureau - AstraZeneca; Merck; Roche; Varian Medical Systems |
Research Funding - Varian Medical Systems |
Travel, Accommodations, Expenses - Varian Medical Systems |
| |
|
Consulting or Advisory Role - Merck Sharp & Dohme |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Employment - Michigan Orthopaedic Surgeons/Beaumont Hospital (I) |
Consulting or Advisory Role - Varian Medical Systems |
Research Funding - Varian Medical Systems |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
|
Consulting or Advisory Role - AVID Radiopharmaceuticals; Capella Imaging; Curium Pharma; ImaginAb; Progenics |
Research Funding - Blue Earth Diagnostics (Inst); ImaginAb (Inst); Progenics (Inst) |
Travel, Accommodations, Expenses - Blue Earth Diagnostics; ImaginAb; Progenics; Siemens (I) |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
|
Stock and Other Ownership Interests - Radialogica |
Consulting or Advisory Role - AstraZeneca; EMD Serono; Varian Medical Systems |
Research Funding - Merck (Inst); Varian Medical Systems (Inst) |
Patents, Royalties, Other Intellectual Property - Noninvasive imaging and treatment system for cardiac arrhythmias WO 2017078757 A1; U.S. Provisional Application No. 62/598,162 Entitled SYSTEM AND METHOD FOR DETERMINING SEGMENTS FOR ABLATION |
Travel, Accommodations, Expenses - Siemens Healthineers |
| |
|
Leadership - TibaRay, Inc. |
Stock and Other Ownership Interests - TibaRay, Inc. |
Research Funding - Varian Medical Systems (Inst) |
| |
|
Speakers' Bureau - AstraZeneca |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Speakers' Bureau - AstraZeneca |
| |
|
Patents, Royalties, Other Intellectual Property - I hold a US patent for "mini beam collimator for medical linear accelerators" Patent No.: US 10,702,711 B2 Date of Patent: Jul. 7,2020 |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - AstraZeneca/MedImmune; Mevion Medical Systems |
Consulting or Advisory Role - Genentech; Varian Medical Systems |
| |
|
Consulting or Advisory Role - AstraZeneca |
Research Funding - AstraZeneca; Elekta |